(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3, 3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo- tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1β and IL-18

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 2, 2007, Pages 509-516

  Wannamaker, Woods ^a   Davies, Robert ^a   Namchuk, Mark ^a   Pollard, John ^a   Ford, Pamella ^a   Ku, George ^a   Decker, Caroline ^a   Charifson, Paul ^a   Weber, Peter ^a   Germann, Ursula A ^a   Kuida, Keisuke ^a   Randle, John C R ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [[1 (4 AMINO 3 CHLORO PHENYL)METHANOYL]AMINO] 3,3 DIMETHYL BUTANOYL] PYRROLIDINE 2 ARBOXYLIC ACID (2 ETHOXY 5 OXO TETRAHYDRO FURAN 3 YL)AMIDE; ANTIINFLAMMATORY AGENT; CASPASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 18; INTERLEUKIN 1BETA; OXAZOLONE; PREDNISOLONE; UNCLASSIFIED DRUG; VRT 043198; VX 765;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

4-AMINOBENZOIC ACID; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; ARTHRITIS, EXPERIMENTAL; CASPASE 1; DIPEPTIDES; HUMANS; HYPERSENSITIVITY, DELAYED; INTERLEUKIN-18; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED DBA; OXAZOLONE; PROTEASE INHIBITORS;

EID: 34247219224     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.111344     Document Type: Article

References (40)

1. Antonopoulos C, Cumberbatch M, Dearman RJ, Daniel RJ, Kimber I, and Groves RW (2001) Functional caspase-1 is required for Langerhans cell migration and optimal contact sensitization in mice. J Immunol 166:3672- 3677.
2. Askenase PW (2001) Yes T cells, but three different T cells (alphabeta, gammadelta and NK T cells), and also B-1 cells mediate contact sensitivity. Clin Exp Immunol 125:345-350.
3. Braddock M and Quinn A (2004) Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov 3:330-339.
4. Campbell IK, O'Donnell K, Lawlor KE, and Wicks IP (2001) Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Investig 107:1519-1527.
5. Covert MW, Leung TH, Gaston JE, and Baltimore D (2005) Achieving stability of lipopolysaccharide-induced NF-B activation. Science (Wash DC) 309:1854-1857.
6. Cumberbatch M, Dearman RJ, Antonopoulos C, Groves RW, and Kimber I (2001) Interleukin (IL)-18 induces Langerhans cell migration by a tumour necrosis factor-α- and IL-1β-dependent mechanism. Immunology 102:323-330.
7. Dinarello CA (2002) The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20:S1-S13.
8. Earnshaw WC, Martins LM, and Kaufmann SH (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68:383-424.
9. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF, et al. (1989) Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J Exp Med 170:1627-1633.
10. Fitzgerald AA, LeClercq SA, Yan A, Homik JE, and Dinarello CA (2005) Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 52:1794-1803.
11. Fox T, de Miguel E, Mort JS, and Storer AC (1992) Potent slow-binding inhibition of cathepsin B by its propeptide. Biochemistry 31:12571-12576.
12. Goldring SR and Gravallese EM (2000) Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 12:195-199.
13. Hoshino T, Kawase Y, Okamoto M, Yokota K, Yoshino K, Yamamura K, Miyazaki J, Young HA, and Oizumi K (2001) Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J Immunol 166:7014-7018.
14. Iwakura Y (2002) Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev 13:341-355.
15. Joosten LA, Helsen MM, van de Loo FA, and van den Berg WB (1996) Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 39:797-809.
16. Ku G, Faust T, Lauffer LL, Livingston DJ, and Harding MW (1996) Interleukin-1β converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine 8:377-386.
17. Ku G, Ford P, Raybuck SA, Harding MW, and Randle JCR (2001) Selective interleukin-1β converting enzyme (ICE/caspase-1) inhibition with pralnacasan (HMR 3480/VX-740) reduces inflammation and joint destruction in murine type II collagen-induced arthritis (CIA). Arthritis Rheum 44:S241.
18. Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS, and Flavell RA (1995) Altered cytokine export and apoptosis in mice deficient in interleukin-1β converting enzyme. Science (Wash DC) 267:2000-2003.
19. Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, McDowell J, Paskind M, Rodman L, Salfeld J, et al. (1995) Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock. Cell 80:401-411.
20. Loher F, Bauer C, Landauer N, Schmall K, Siegmund B, Lehr HA, Dauer M, Schoenharting M, Endres S, and Eigler A (2004) The interleukin-1β- converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther 308:583-590.
21. Martinon F and Tschopp J (2004) Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117:561-574.
22. Mori L, Iselin S, De Libero G, and Lesslauer W (1996) Attenuation of collageninduced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol 157:3178-3182.
23. Murray N, Zoerkler N, Brown T, and Bonhomme Y (1994) LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Int J Immunopharmacol 16:675-683.
24. Naik SM, Cannon G, Burbach GJ, Singh SR, Swerlick RA, Wilcox JN, Ansel JC, and Caughman SW (1999) Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with proinflammatory mediators and dinitrochlorobenzene. J Investig Dermatol 113:766-772.
25. Neidel J, Schulze M, and Lindschau J (1995) Association between degree of boneerosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis. Inflamm Res 44:217-221.
26. Pascual V, Allantaz F, Arce E, Punaro M, and Branchereau J (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201:1479-1486.
27. Rioja I, Bush KA, Buckton JB, Dickson MC, and Life PF (2004) Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. Clin Exp Immunol 137:65-73.
28. Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, and van den Berg W (2003) Pralnacasan, an inhibitor of interleukin-1β converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthr Cartil 11:738-746.
29. Saijo S, Asano M, Horai R, Yamamoto H, and Iwakura Y (2002) Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum 46:533-544.
30. Smith DJ, McGuire MJ, Tocci MJ, and Thiele DL (1997) IL-1βconvertase (ICE) does not play a requisite role in apoptosis induced in T lymphoblasts by Fas-dependent or Fas-independent CTL effector mechanisms. J Immunol 158:163-170.
31. Stack JH, Beaumont K, Larsen PD, Straley KS, Henkel GW, Randle JCR, and Hoffman HM (2005) ICE/Caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from FCAS patients. J Immunol 175:2630-2634.
32. Stoll S, Jonuleit H, Schmitt E, Muller G, Yamauchi H, Kurimoto M, Knop J, and Enk AH (1998) Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol 28:3231-3239.
33. Thalappilly S, Sadasivam S, Radha V, and Swarup G (2006) Involvement of caspase 1 and its activator Ipaf upstream of mitochondrial events in apoptosis. FEBS J. 273:2766-2778.
34. Ting JP, Kastner DL, and Hoffman HM (2006) CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol 6:183-195.
35. van den Berg WB (2002) Is there a rationale for combined TNF and IL-1 blocking in arthritis? Clin Exp Rheumatol 20:S21-S25.
36. Wang B, Feliciani C, Howell BG, Freed I, Cai Q, Watanabe H, and Sauder DN (2002) Contribution of Langerhans cell-derived IL-18 to contact hypersensitivity. J Immunol 168:3303-3308.
37. Wannamaker M and Davies R (2001) inventors; Vertex Pharma, assignee. Prodrug of an ICE inhibitor. World Patent WO0190063. 2001 Nov 29
38. Wooley PH, Dutcher J, Widmer MB, and Gillis S (1993) Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 151:6602-6607.
39. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, Akira S, and Nakanishi K (1998) IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J Immunol 161:3400-3407.
40. Zepter K, Haffner A, Soohoo LF, De Luca D, Tang HP, Fisher P, Chavinson J, and Elmets CA (1997) Induction of biologically active IL-1γ-converting enzyme and mature IL-1γ in human keratinocytes by inflammatory and immunologic stimuli. J Immunol 159:6203-6208.